Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines

Abstract

Imatinib mesylate is currently the drug of choice to treat chronic myeloid leukemia. However, patient resistance and cytotoxicity make secondary lines of treatment, such as omacetaxine mepesuccinate, a necessity. Given that drug cytotoxicity represents a major problem during treatment, it is essential to understand the biological pathways affected to better… (More)
DOI: 10.1186/1755-8794-5-37

Topics

7 Figures and Tables

Cite this paper

@inproceedings{Kulkarni2012AssociationOD, title={Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines}, author={Hemant Kulkarni and Harald H. G{\"{o}ring and Vincent Paul Diego and Shelley A. Cole and Ken Walder and Greg R. Collier and John Blangero and Melanie A. Carless}, booktitle={BMC Medical Genomics}, year={2012} }